Clinical Trial Update: Aim to Reduce Movements in Tardive Dyskinesia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial update for an attempt to reduce movements in tardive dyskinesia by Auspex Pharmaceuticals; the study is completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Snippet

Sponsor: Auspex Pharmaceuticals, Inc. | Conditions: Tardive Dyskinesia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-03-20